Trials / Completed
CompletedNCT05352997
Beta-lactams Therapeutic Drug Monitoring in Critically Ill Patients
Key Factors of Target Serum Concentrations Attainment From Beta-lactams Therapeutic Drug Monitoring in Critically Ill Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 156 (actual)
- Sponsor
- Centre Hospitalier Universitaire de Nīmes · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The population of these monocentric and retrospective study includes patients hospitalized in one of the critical care services of Nîmes' community hospital. The objective is to determine the key factors that lead to satisfactory beta-lactams serum concentrations in critically ill patients. Clinical and biological features, as well as risk scores are collected and recorded into an electronic Case Report Form. The primary outcome is to show the main characteristics related to adequate beta-lactams serum concentrations in critically ill inpatients. Secondary outcomes include the key factors related to inadequate beta-lactams serum concentrations in critically ill inpatients, Therapeutic Drug Monitoring (TDM) impact in the achievement of target beta-lactams serum concentration and the correlation between Aminoglycosides and Beta-lactams serum concentrations. Do both antibiotics have similar elimination kinetics ?
Conditions
Timeline
- Start date
- 2018-01-01
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
- First posted
- 2022-04-29
- Last updated
- 2025-12-04
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05352997. Inclusion in this directory is not an endorsement.